Lineage Historical Income Statement
| LCTX Stock | USD 0.61 0.01 1.67% |
Historical analysis of Lineage Cell income statement accounts such as Gross Profit of 8.7 M can show how well Lineage Cell Therapeutics performed in making a profits. Evaluating Lineage Cell income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Lineage Cell's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Lineage Cell Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Lineage Cell Therapeutics is a good buy for the upcoming year.
Lineage |
About Lineage Income Statement Analysis
Lineage Cell Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Lineage Cell shareholders. The income statement also shows Lineage investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Lineage Cell Income Statement Chart
Add Fundamental
Interest Expense
The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.Total Revenue
Total revenue comprises all receipts Lineage Cell Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Lineage Cell Therapeutics. It is also known as Lineage Cell overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Cost Of Revenue
Cost of Revenue is found on Lineage Cell Therapeutics income statement and represents the costs associated with goods and services Lineage Cell provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Lineage Cell's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Lineage Cell Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lineage Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. At this time, Lineage Cell's Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 6 M in 2024, whereas Other Operating Expenses is likely to drop slightly above 20.7 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 51.7M | 36.5M | 33.0M | 21.0M | Cost Of Revenue | 1.4M | 728K | 671K | 583.4K |
Lineage Cell income statement Correlations
Click cells to compare fundamentals
Lineage Cell Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lineage Cell income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | (15.4M) | 2.1M | 887K | 727K | 692K | 922.5K | |
| Interest Expense | 1.7M | 5.2M | 2K | 5.2M | 6.0M | 6.0M | |
| Total Revenue | 1.5M | 773K | 3.9M | 14.7M | 8.9M | 9.4M | |
| Gross Profit | 1.1M | 388K | 2.5M | 14.0M | 8.3M | 8.7M | |
| Other Operating Expenses | 40.4M | 27.2M | 53.1M | 37.2M | 33.7M | 20.7M | |
| Operating Income | (38.9M) | (26.4M) | (49.2M) | (22.5M) | (24.7M) | (26.0M) | |
| Ebit | (38.9M) | (26.5M) | (49.2M) | (22.5M) | (24.7M) | (26.0M) | |
| Ebitda | (54.3M) | (24.4M) | (48.3M) | (21.8M) | (24.0M) | (25.2M) | |
| Cost Of Revenue | 412K | 385K | 1.4M | 728K | 671K | 583.4K | |
| Total Operating Expenses | 39.9M | 26.8M | 51.7M | 36.5M | 33.0M | 21.0M | |
| Income Before Tax | (19.2M) | (21.9M) | (43.3M) | (25.8M) | (23.3M) | (22.1M) | |
| Total Other Income Expense Net | 19.6M | 4.5M | 5.9M | (3.3M) | 1.5M | 1.4M | |
| Net Income | (11.8M) | (20.7M) | (38.6M) | (26.4M) | (21.5M) | (20.4M) | |
| Income Tax Expense | (7.4M) | (1.2M) | (4.7M) | 541K | (1.8M) | (1.9M) | |
| Research Development | 17.9M | 12.3M | 33.9M | 14.0M | 15.7M | 12.9M | |
| Selling General Administrative | 24.0M | 15.6M | 18.2M | 22.5M | 17.3M | 11.0M | |
| Net Income From Continuing Ops | (26.6M) | (20.7M) | (43.3M) | (26.4M) | (21.5M) | (22.6M) | |
| Non Operating Income Net Other | 18.0M | 4.5M | 5.9M | (4.1M) | (4.7M) | (4.5M) | |
| Net Income Applicable To Common Shares | (11.7M) | (20.6M) | (43.0M) | (26.3M) | (30.2M) | (31.7M) | |
| Minority Interest | (118K) | (36K) | (251K) | (80K) | (7K) | (7.4K) | |
| Tax Provision | (7.4M) | (1.2M) | (2.2M) | 541K | (1.8M) | (1.9M) | |
| Interest Income | 17.1M | 1.0M | 2K | 829K | 1.6M | 1.5M | |
| Net Interest Income | 1.7M | 1.0M | 2K | 829K | 1.6M | 1.7M | |
| Reconciled Depreciation | 3.1M | 2.1M | 887K | 727K | 692K | 657.4K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lineage Stock Analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.